Related Experiment Video
Updated: May 25, 2025
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.6K
Novel Tissue-Specific Multifunctionalized Nanotechnological Platform Encapsulating Riluzole Against Motor Neuron
Gerard Esteruelas1,2,3, Miren Ettcheto4,5,6,7, Isabel Haro3
1Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, 08028, Spain.
International Journal of Nanomedicine
|February 26, 2025
Summary
A new nanostructured carrier selectively delivers Riluzole to motor neurons, improving treatment for Amyotrophic Lateral Sclerosis (ALS) and reducing side effects. This targeted approach enhances drug efficacy for motor neuron diseases.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Motor neuron diseases, including Amyotrophic Lateral Sclerosis (ALS), involve progressive degeneration of motor neurons, leading to paralysis and death.
- Current treatments like Riluzole are limited by the need for high doses, causing severe side effects in non-target organs.
- There is a critical need for strategies to enhance Riluzole delivery specifically to motor neurons, minimizing systemic toxicity.
Purpose of the Study:
- To develop and characterize a novel multifunctional nanostructured carrier for targeted Riluzole delivery to motor neurons.
- To evaluate the in vitro and in vivo efficacy and safety of this targeted drug delivery system.
Main Methods:
- Development of peptide (pVEC) and PEG-labeled PLGA nanoparticles encapsulating Riluzole.
- Characterization of nanoparticle properties for central nervous system (CNS) drug release.
- In vitro and in vivo assessment of nanoparticle biodistribution and Riluzole concentration in target and non-target organs.
Main Results:
- The developed nanoparticles demonstrated suitable characteristics for Riluzole release in the CNS.
- Targeted nanoparticles were detected in motor neurons within 1 hour of administration.
- Significantly reduced Riluzole concentration was observed in non-therapeutic organs, indicating reduced systemic side effects.
Conclusions:
- A novel, tissue-targeted nanodelivery system for Riluzole has been successfully developed and characterized.
- This system enhances Riluzole's CNS biodistribution, showing promise for treating motor neuron diseases like ALS.
- The targeted approach offers a potential strategy to improve therapeutic efficacy while mitigating adverse effects.
